RESUMEN
BACKGROUND & AIMS: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (eg, COVID-19). This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure, and high risk of short-term death. METHODS: This prospective cohort study analyzed a comprehensive set of data, including genetic ancestry and race among several others, in 1274 patients with acutely decompensated cirrhosis who were nonelectively admitted to 44 hospitals from 7 Latin American countries. RESULTS: Three hundred ninety-five patients (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had a higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4% vs 59.6%, respectively). The median percentage of African genetic ancestry was low among patients with ACLF and among those without ACLF. In terms of race, a higher percentage of patients with ACLF than patients without ACLF were Native American and a lower percentage of patients with ACLF than patients without ACLF were European American or African American. In multivariable analyses that adjusted for differences in sociodemographic and clinical characteristics, the odds ratio for ACLF at enrollment was 1.08 (95% CI, 1.03-1.13) with Native American genetic ancestry and 2.57 (95% CI, 1.84-3.58) for Native American race vs European American race CONCLUSIONS: In a large cohort of Latin American patients with acutely decompensated cirrhosis, increasing percentages of Native American ancestry and Native American race were factors independently associated with ACLF at enrollment.
Asunto(s)
Insuficiencia Hepática Crónica Agudizada , COVID-19 , Humanos , América Latina/epidemiología , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/epidemiología , Cirrosis Hepática/genética , Estudios Prospectivos , COVID-19/complicaciones , Insuficiencia Hepática Crónica Agudizada/diagnóstico , Insuficiencia Hepática Crónica Agudizada/epidemiología , Insuficiencia Hepática Crónica Agudizada/genética , Inflamación/complicaciones , PronósticoRESUMEN
Objetivo; evaluar la aplicabilidad del modelo diagnóstico propuesto por el Grupo Internacional de Hepatitis Autoinmune (G1HA). Metodología: estudio retrospectivo, observacional, no analítico de 28 pacientes con diagnóstico de Hepatitis Autoinmune (HA1) de la ciudad de Medellín- Colombia. Resultados; se analizaron 28 pacientes con diagnóstico de HAI. Según el modelo de criterios diagnósticos de 1992 aplicado a los pacientes antes del inicio del tratamiento, 25 por ciento tuvieron diagnostico definitivo y 53 por ciento diagnóstico probable. Al aplicar los nuevos criterios, 14 por ciento tenían diagnostico definitivo y 64 por ciento probable. En ambos modelos 22 por ciento de los pacientes no alcanzaron el puntaje para clasificarlos como HA1. La concordancia entre el diagnóstico clínico y los criterios del GIHA fue de 78. 5 por ciento con ambos puntajes. Conclusiones: ambos modelos son útiles para el diagnóstico de hepatitis autoinmune. El modelo de 1998 es más especifico en nuestro estudio